What question did this study set out to answer?

To identify salivary biomarkers for temporomandibular joint osteoarthritis (TMJOA) using RNA sequencing and clinical validation.

March 19, 2026Open Access

View Full Paper

Whole Transcriptomic Analysis Identifies Candidate Biomarkers from Saliva of Temporomandibular Joint Osteoarthritis Patients

NANawal AlketbiUniversity of Sharjah AAAlaa Muayad AltaieUniversity of Sharjah RAReem Sami AlhamidiUniversity of Sharjah

Key Points

To identify salivary biomarkers for temporomandibular joint osteoarthritis (TMJOA) using RNA sequencing and clinical validation.
RNA sequencing of saliva samples from TMJOA patients and healthy controls
Analysis of publicly available transcriptomic dataset GSE205389
Validation of differentially expressed genes (DEGs) using qRT-PCR
Gene set enrichment analysis (GSEA) to explore biological pathways
Integration of clinical and in silico RNA sequencing datasets
Identified 2758 and 3548 DEGs in clinical and in silico datasets, respectively, with 743 overlapping genes.
Highlighted immune-related, metabolic, and osteoclast-related pathways.
Validated four genes—CRIP1, PPA1, TARS1 (statistically significant), and GCLC (non-significant trend)—showing elevated expression in TMJOA patients.
Upregulation of PTK2B, ABL1, TNF, and IL-1B supports their relevance as salivary biomarkers.

Abstract

Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by progressive cartilage degeneration and subchondral bone remodeling, resulting in chronic pain and functional impairment. Although conservative treatments such as physical therapy and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used, their effectiveness is limited due to the poorly understood pathophysiology of TMJOA. Identifying reliable molecular biomarkers is essential to improving early diagnosis and guiding therapeutic development. This proof-of-concept study aims to identify candidate salivary biomarkers for TMJOA using an integrative approach combining clinical validation with in silico analysis. RNA sequencing was performed on saliva samples from TMJOA patients and healthy controls. In parallel, publicly available transcriptomic dataset GSE205389 was analyzed to identify differentially expressed genes (DEGs). DEGs were validated using qRT-PCR. Gene set enrichment analysis (GSEA) and Metascape were used to explore biological pathways associated with TMJOA. Integration of clinical and in silico RNA sequencing datasets identified 2758 and 3548 DEGs, respectively, with 743 overlapping genes. Pathway enrichment analyses highlighted immune-related, metabolic and osteoclast-related pathways. Four genes, CRIP1, PPA1 and TARS1 (statistically significant) and GCLC (non-significant trend), were validated by qRT-PCR in the clinical saliva samples, confirming elevated expression in TMJOA patients. Validation of the in silico dataset showed an upregulation of PTK2B, ABL1, TNF and IL-1B, supporting their relevance as salivary biomarkers in TMJOA. This exploratory study identifies four candidate salivary genes, CRIP1, PPA1, TARS1 and GCLC, as candidate salivary biomarkers for TMJOA, offering insights into disease mechanisms. Larger studies are needed to validate these findings and assess their clinical utility.

AIに質問

Bookmark

View Full Paper

Cite This Study

Alketbi et al. (Tue,) studied this question.

synapsesocial.com/papers/69bb9279496e729e6297fc1c https://doi.org/https://doi.org/10.3390/ijms27062727

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper